SCHEMBL6539287

SCHEMBL6539287

CC[CH]c1ccccc1OCCCCC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
KMT2A Q03164 2/20 0.50
CYP3A4 P08684 2/20 0.50
MEN1 O00255 1/20 0.50
NR1I2 O75469 1/20 0.50
LMNA P02545 1/20 0.50
CHRM2 P08172 1/20 0.50
ADRA2A P08913 1/20 0.50
MAPT P10636 1/20 0.50
OPRK1 P41145 1/20 0.50
HTR2B P41595 1/20 0.50
SLC6A3 Q01959 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
LTA4H P09960 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6756008 0.98 LMNA (0.53) CYP1A2CYP2C9CYP2C19KMT2ACYP3A4
SCHEMBL6538963 0.89 CYP1A2 (0.49) CYP1A2CYP2C9CYP2C19KMT2ACYP3A4
SCHEMBL27533288 0.88 ALDH1A1 (0.50) CYP1A2CYP2C9CYP2C19KMT2AMEN1
SCHEMBL6538942 0.87 MEN1 (0.50) CYP1A2CYP2C9CYP2C19KMT2ACYP3A4
SCHEMBL6538482 0.87 MEN1 (0.50) CYP1A2CYP2C9CYP2C19KMT2ACYP3A4
SCHEMBL9173228 0.85 CYP1A2 (0.53) CYP1A2CYP2C9CYP2C19KMT2ACYP3A4
SCHEMBL677507 0.85 CYP1A2 (0.52) CYP1A2CYP2C9CYP2C19KMT2ACYP3A4
SCHEMBL6651604 0.83 CYP1A2 (0.63) CYP1A2CYP2C9CYP2C19KMT2ACYP3A4
SCHEMBL30096940 0.83 CYP1A2 (0.63) CYP1A2CYP2C9CYP2C19KMT2ACYP3A4
SCHEMBL2924589 0.83 LMNA (0.53) CYP1A2CYP2C9CYP2C19KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6743776-B2 ANTIFUNGAL, BETA-1,3-GLUCAN SYNTHASE INHIBITOR, PNEUMOCYSTIS CARINII; AMIDATION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-01 US disclosed
US-20020193560-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY ASTELLAS PHARMA INC. (JP) 2002-12-19 US disclosed
EP-0941236-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-09-15 EP disclosed
WO-1998023637-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193560-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY NGLY1, CHIT1, MANBA CYP1A2 3431/4885CYP2C9 2777/4885CYP2C19 2409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.